BBS as an investment


The BBS’s core competence includes easy-to-use and ready-to-use bone formation and healing enhancing bone replacement implant development and manufacturing. The BBS develops, manufactures and sells bone substitutes for orthopedic use globally. Selected partners are also used for sales and distribution. The application process for the CE-mark has been initiated.


BBS-Bioactive Bone Substitutes Plc’s vision is to be one of the leading international companies in the field of bioactive implants (orthobiological products), with the aim of dealing with various types of orthopedic damages and bone healing problems.


BBS-Bioactive Bone Substitutes Plc seeks out its position as one of the leading players in the field of bioactive implants that improve bone enhancement. The company’s aim is to provide added value for shareholders with its unique innovative product development and commercialization on the rapidly expanding global bone substitute markets.

Towards a product with a strong market position

BBS’s employees are dedicated and committed to use the company’s technology to improve the results of both surgical care and patient recovery.

BBS-Bioactive Bone Substitutes Plc (BBS) is a health technology company that develops innovative biologically active medical implants for orthopedic surgery.

BBS’s core competence includes development and manufacturing of easy-to-use and ready-to-use bone implants that enhance bone forming and healing. Bone substitutes are intended for use in the treatment of various types of injury and illnesses of bone tissue in place of their own bone and bank bone transplant. Various injuries and diseases can cause defects in bones or other problems. These problems may occur, for example, in trauma and prosthetic surgery in the event of illness.

Certain bone healing problems and injuries require either bone transplant (autografting, allografting) or bone substitute implant use.

In particular, bone defects due to various causes and bone defect are common bone problems in orthopedics. Orthobiological products are biological materials that are used to enhance the healing of bone, damaged muscules, tendons and ligaments.

Orthobiological products support tissue improvement by utilizing body regeneration potential at cellular levels and accelerating healing by applying biology or biochemistry to the replacement of musculosceletal tissues. Orthobiological products are used in arthritis, trauma and soft tissue and spinal surgery.


Why to invest in BBS

The introduction of new orthopedic cutting technologies and the increased number of operations caused by the aging of the population are key drivers for growth in the global bone substitute market.

  • BBS is a medical research and product development company applying for funding for the preparation of process of sale licensing and for launching sales and marketing.
  • The market of bone substitutes is big, globally 2,3-2,7 billion US dollars.
  • The characteristics of the product have been established in a scientific study and in clinical trials prior to the CE-mark application.
  • The product is based on 20 years of long-term medical research.
  • Own production plant which is approved by FIMEA for protein extract manufacturing.


Product development in the medical field is long-term, controlled by the authorities and involves significant risks. The turnover begins to accumulate only when after the product has been subjected to the necessary phased tests and has received the necessary regulatory approvals after the product development phase. This may take several years, in some cases for up to tens of years.



BBS-Bioactive Bone Substitutes Plc operates in the field of orthopedic products and is segmented into orthobiological products. Orthobiological products mean biological materials that are used to enhance the healing of injured muscles, tendons and ligaments.

The sales of orthobiological products were 4,6 billion US dollars (market size from various sources of 4,5-6,0 billion US dollars) globally. The annual growth was 2,4-2,8 percent. The size of the market for the company’s current target market (allograft and synthetic products) was globally about 2,3-2,7 billion US dollars. The bone substitute market is expected to rise to 3,6 billion US dollars by 2024.

The introduction of new operating techniques, invasive surgery requirements and increased operating numbers are the key drivers for growth in the global bone substitute market.

The largest market areas for bone substitutes are North America, EU and Asia. In the EU region, sales require the obtained CE-mark and in the USA the requirement is FDA-approval.